Skip to main content
. 2022 Jan 26;28(1):2–13. doi: 10.1097/PPO.0000000000000567

FIGURE 2.

FIGURE 2

Timing of BM evaluations and treatment decision making for venetoclax-based regimens in AML. Count recovery implies peripheral blood counts to CR criteria, i.e., ANC >1 × 109/L and platelet count >100 × 109/L, or at least until CRh, i.e., ANC >0.5 × 109/L and platelet count >50 × 109/L. C indicates cycle; D, day; FLT3i, FLT3 inhibitor; VEN, venetoclax.